文献速递神经肿瘤

研究与作者特征对神经肿瘤临床试验的试验资助与自我报告利益冲突的影响

The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials.
PubMed 文献 · J Neurooncol · 2018-06-04

该研究通过MEDLINE检索2010至2015年中枢神经系统肿瘤临床试验,评估资助来源、自我报告利益冲突(COI)与研究及作者特征的关系。共纳入319项试验,多数为胶质瘤(55.2%)和II期试验(59.2%),药物疗法占83.0%。多因素分析显示干预类型、期刊影响因子、COI存在和研究结论是资助的显著预测因素;疾病类型、期刊影响因子、干预类型和资助来源是COI的显著预测因素。

要点

  • 83.1%的研究披露了资助来源,其中32.6%仅来自工业界,33.9%来自学术或合作组,10.7%为混合资助模式。
  • 85.9%的试验报告了COI数据,其中56.2%报告无COI,43.8%报告相关COI。
  • 多因素分析中,药物试验、较高影响因子、存在COI以及中性或阴性研究结论与外部资助相关;药物试验、较高影响因子和胶质瘤试验与COI存在相关。

核心结论

  • 多数中枢神经系统肿瘤临床试验报告了外部资助来源和非相关COI。
  • 药物试验、较高影响因子、存在COI以及中性或阴性研究结论与外部资助相关。
  • 药物试验、较高影响因子和胶质瘤试验与COI存在相关。

研究设计与样本

  • 通过MEDLINE检索“Central Nervous System Neoplasms”[Mesh]的原始临床试验,评估资助来源(工业界、学术或合作组、无、未描述)、COI(呈现、无或未报告)、临床试验及作者特征之间的关系。
  • 2010年至2015年间共319项临床试验符合条件。

主要发现

  • 多数研究涉及原发性胶质瘤(55.2%)且为II期临床试验(59.2%)。
  • 药物疗法在83.0%的临床试验中被研究,其余研究探讨手术或放疗。
  • 少数论文发表在影响因子高于10的期刊(16%)或北美和欧洲以外的地区(20.4%)。
  • 总体83.1%的研究披露了资助来源:32.6%仅来自工业界,33.9%来自学术或合作组,10.7%来自混合资助模式。
  • 85.9%的试验报告了COI数据,其中56.2%报告无COI,43.8%报告相关COI。

关键数值与推荐

  • 单因素分析中资助(工业界和/或学术界)的显著预测因素为研究设计、干预类型、期刊影响因子、研究结论、COI透明度和COI存在。
  • 多因素分析中,干预类型(P < 0.001)、期刊影响因子(P = 0.003)、COI存在(P < 0.001)和研究结论(P = 0.003)仍是资助的显著预测因素。
  • 预测COI的单因素分析显著变量为疾病类型、干预类型、期刊影响因子、资助来源和干预组与赞助者相关。
  • 多因素分析中,疾病类型(P = 0.003)、期刊影响因子(P < 0.001)、干预类型(P = 0.001)和资助来源(P = 0.008)仍是显著因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PROPOSE: To examine the association between trial sponsorship sources, self-reported conflicts of interest (COI), and study and author characteristics in central nervous system (CNS) oncology clinical trials (CT). METHODS: MEDLINE search was performed for original CT on "Central Nervous System Neoplasms"[Mesh]. The investigators assessed for relationships between funding source (industry, academic or cooperative, none, not described), COI (presented, none, or not reported), CT, and author characteristics. RESULTS: From 2010 to 2015, 319 CT were considered eligible. The majority of the studies involved primary gliomas (55.2%) and were Phase II CT (59.2%). Drug therapy was investigated in 83.0% of the CT. The remaining studies investigated surgery or radiotherapy. A minority of papers were published in journals with impact factor (IF) higher than > 10 (16%) or in regions other than North America and Europe (20.4%). Overall, 83.1% of studies disclosed funding sources: 32.6% from industry alone, 33.9% from an academic or cooperative group, and 10.7% from a mixed funding model. COI data was reported by 85.9% of trials, of which 56.2% reported no COI and 43.8% reported a related COI. Significant predictors for sponsorship (industry and/or academia) on univariate analysis were study design, type of intervention, journal impact factor, study conclusion, transparency of COI and presence of COI. On multivariate analysis, type of intervention, (P < 0.001), journal impact factor (IF) (P = 0.003), presence of COI (P < 0.001) and study conclusion (P = 0.003) remained significant predictors of sponsorship. For predicting COI, significant variables on univariate analysis were disease type, type of intervention, journal IF, funding source, and intervention arm being related to sponsor. On multivariate analysis, disease type (P = 0.003), journal IF (P < 0.001), type of intervention (P = 0.001), and funding source (P = 0.008) remained significant. CONCLUSIONS: The majority of CNS CT reported some external funding sources and non-related COI. We identified that drug trials, higher IF, presence of COI, and a neutral or negative study conclusion are associated with external funding. Likewise drug trials, higher IF, and glioma trials are associated with presence of COI.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Raman S, Moraes FY, Mendez LC, et al. The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials. J Neurooncol. 2018. PMID: 29869023. doi:10.1007/s11060-018-2860-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。